The therapeutic potential of niche-specific mesenchymal stromal cells for spinal cord injury repair

Lindsay, S. L. and Barnett, S. C. (2021) The therapeutic potential of niche-specific mesenchymal stromal cells for spinal cord injury repair. Cells, 10(4), 901. (doi: 10.3390/cells10040901) (PMID:33919910) (PMCID:PMC8070966)

[img] Text
235969.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

The use of mesenchymal stem/stromal cells (MSCs) for transplant-mediated repair represents an important and promising therapeutic strategy after spinal cord injury (SCI). The appeal of MSCs has been fuelled by their ease of isolation, immunosuppressive properties, and low immunogenicity, alongside the large variety of available tissue sources. However, despite reported similarities in vitro, MSCs sourced from distinct tissues may not have comparable biological properties in vivo. There is accumulating evidence that stemness, plasticity, immunogenicity, and adaptability of stem cells is largely controlled by tissue niche. The extrinsic impact of cellular niche for MSC repair potential is therefore important, not least because of its impact on ex vivo expansion for therapeutic purposes. It is likely certain niche-targeted MSCs are more suited for SCI transplant-mediated repair due to their intrinsic capabilities, such as inherent neurogenic properties. In addition, the various MSC anatomical locations means that differences in harvest and culture procedures can make cross-comparison of pre-clinical data difficult. Since a clinical grade MSC product is inextricably linked with its manufacture, it is imperative that cells can be made relatively easily using appropriate materials. We discuss these issues and highlight the importance of identifying the appropriate niche-specific MSC type for SCI repair.

Item Type:Articles
Additional Information:Funding: This research was funded by the Multiple Sclerosis Society of Great Britain (SLL, grant number 56), Medical Research Council (Grant number MR/V00381X/1) and the Chief Scientist Office (Grant number TCS1922).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Barnett, Professor Susan and Lindsay, Dr Susan
Creator Roles:
Lindsay, S. L.Writing – original draft
Barnett, S. C.Writing – review and editing
Authors: Lindsay, S. L., and Barnett, S. C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Cells
Publisher:MDPI
ISSN:2073-4409
ISSN (Online):2073-4409
Published Online:14 April 2021
Copyright Holders:Copyright © 2021 by the authors
First Published:First published in Cells 10(4):901
Publisher Policy:Reproduced under a Creative Commons Licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
309989Heparin mimetics: Novel non-anticoagulant compounds to promote CNS repairSusan BarnettMedical Research Council (MRC)MR/V00381X/1III - Immunology